3D Cell-Based Assays for Drug Discovery Services
The drug discovery services process is known to be very complex, lengthy and expensive: developing a new drug usually takes over 10 years and can often cost as much as £500 million due to the high failure rate of drug candidates in phase I, II and III clinical trials. At the early stages in this process, standard biochemical assays are traditionally employed for screening of a large number of compounds, followed by cell-based assays and animal studies. Cell-based assays are usually carried out in flat-bottom, multi-well tissue culture plates, i.e. in “2D”. Albeit these assays are cheap and easy to set up, they are a rather poor approximation of tissue in living organisms and hence frequently lead to false results, which can be very costly if discovered at a later stage.
3D cell-based assays can be used to test efficacy of a drug discovery services (e.g. using a cancer model), or reveal potential toxicity issues (e.g. using a hepatocyte culture) by providing a more in vivo-like environment and thereby data, which is more predictive of behaviour in the clinic.
Mimetix Benefits in 3D Cell-Based Assays
Drug Discovery Case Studies with the Mimetix Scaffold
HepG2 hepatocytes regain their functionality over 28 days
HepG2 human liver carcinoma cells cultured in our 3D Mimetix tissue culture plate retain their basic functionality (urea and albumin production) and re-acquire metabolic CYP450 activity over 28 days.
Human breast cancer cell lines show a 3D phenotype
Human breast cancer cell lines show altered behaviour when cultured in the Mimetix scaffold, such as increased resistance to apoptotic and cytotoxic drugs, indicating that they have assumed a 3D phenotype.